Warning: The NCBI web site requires JavaScript to function. more...
The rationale and plan for creating a World Antimalarial Resistance Network (WARN).
Sibley CH, Barnes KI, Plowe CV.
Malar J. 2007 Sep 6;6:118.
Related citations
World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria.
Plowe CV, Roper C, Barnwell JW, Happi CT, Joshi HH, Mbacham W, Meshnick SR, Mugittu K, Naidoo I, Price RN, Shafer RW, Sibley CH, Sutherland CJ, Zimmerman PA, Rosenthal PJ.
Malar J. 2007 Sep 6;6:121.
World Antimalarial Resistance Network I: clinical efficacy of antimalarial drugs.
Price RN, Dorsey G, Ashley EA, Barnes KI, Baird JK, d'Alessandro U, Guerin PJ, Laufer MK, Naidoo I, Nosten F, Olliaro P, Plowe CV, Ringwald P, Sibley CH, Stepniewska K, White NJ.
Malar J. 2007 Sep 6;6:119.
A network to monitor antimalarial drug resistance: a plan for moving forward.
Sibley CH, Barnes KI, Watkins WM, Plowe CV.
Trends Parasitol. 2008 Jan;24(1):43-8. Epub 2007 Nov 26. Review.
World Antimalarial Resistance Network (WARN) II: in vitro antimalarial drug susceptibility.
Bacon DJ, Jambou R, Fandeur T, Le Bras J, Wongsrichanalai C, Fukuda MM, Ringwald P, Sibley CH, Kyle DE.
Malar J. 2007 Sep 6;6:120.
World Antimalarial Resistance Network (WARN) IV: clinical pharmacology.
Barnes KI, Lindegardh N, Ogundahunsi O, Olliaro P, Plowe CV, Randrianarivelojosia M, Gbotosho GO, Watkins WM, Sibley CH, White NJ.
Malar J. 2007 Sep 6;6:122.
Monitoring antimalarial resistance: launching a cooperative effort.
Sibley CH, Guerin PJ, Ringwald P.
Trends Parasitol. 2010 May;26(5):221-4. Epub 2010 Mar 20.
Monitoring antimalarial drug resistance within National Malaria Control Programmes: the EANMAT experience.
East African Network for Monitoring Antimalarial Treatment (EANMAT).
Trop Med Int Health. 2001 Nov;6(11):891-8.
A database of antimalarial drug resistance.
Sibley CH, Ringwald P.
Malar J. 2006 Jun 15;5:48.
[Malaria research for developing countries: the PAL+ program].
Agid F.
Med Trop (Mars). 2003;63(3):236-40. French.
Antimalarial drugs: current status and new developments.
Rathore D, McCutchan TF, Sullivan M, Kumar S.
Expert Opin Investig Drugs. 2005 Jul;14(7):871-83. Review.
Assessment of safety of the major antimalarial drugs.
Chattopadhyay R, Mahajan B, Kumar S.
Expert Opin Drug Saf. 2007 Sep;6(5):505-21. Review.
Economic access to effective drugs for falciparum malaria.
Panosian CB.
Clin Infect Dis. 2005 Mar 1;40(5):713-7. Epub 2005 Feb 3.
World Health Organization/HIVResNet Drug Resistance Laboratory Strategy.
Bertagnolio S, Derdelinckx I, Parker M, Fitzgibbon J, Fleury H, Peeters M, Schuurman R, Pillay D, Morris L, Tanuri A, Gershy-Damet GM, Nkengasong J, Gilks CF, Sutherland D, Sandstrom P.
Antivir Ther. 2008;13 Suppl 2:49-57.
Making malaria-treatment policy in the face of drug resistance.
Bloland PB, Ettling M.
Ann Trop Med Parasitol. 1999 Jan;93(1):5-23. Review.
Current status of malaria chemotherapy and the role of pharmacology in antimalarial drug research and development.
Na-Bangchang K, Karbwang J.
Fundam Clin Pharmacol. 2009 Aug;23(4):387-409. Review.
[The future outlook of antimalarials].
Millet P.
Rev Prat. 2005 Apr 30;55(8):875-9. Review. French.
Implementation of a reference standard and proficiency testing programme by the World Wide Antimalarial Resistance Network (WWARN).
Lourens C, Watkins WM, Barnes KI, Sibley CH, Guerin PJ, White NJ, Lindegardh N.
Malar J. 2010 Dec 25;9:375.
Will a global subsidy of new antimalarials delay the emergence of resistance and save lives?
Laxminarayan R, Over M, Smith DL.
Health Aff (Millwood). 2006 Mar-Apr;25(2):325-36.
The global portfolio of new antimalarial medicines under development.
Olliaro P, Wells TN.
Clin Pharmacol Ther. 2009 Jun;85(6):584-95. Epub 2009 Apr 29. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on